Eupraxia Pharmaceuticals is trading at $7.30 (5.5% up) in pre-market, extending its multi-day rebound from late June levels as investors react to sustained bullish sentiment from Wall Street.
- Cantor Fitzgerald recently reiterated an Overweight rating and a $19 price target, while other firms maintained Buy ratings and double-digit targets.
- Analysts highlighted optimism surrounding the progress of the EP-104GI trial and the company’s solid cash position.
- The stock's upward momentum continues despite no fresh company news being released on July 9, 2026.